Real-world evidence presented at the 2026 International Stroke Conference shows meaningful improvements in transfer efficiency, helping stroke patients reach advanced treatment faster
SAN FRANCISCO–(BUSINESS WIRE)–#ai–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the presentation of new clinical data at the American Heart Association’s International Stroke Conference (ISC) 2026 demonstrating a 44% reduction in door-in-door-out (DIDO) time — the time required to evaluate, coordinate, and transfer a patient to a comprehensive stroke center — for patients with large vessel occlusion (LVO) stroke in regional care settings.
The study, “Bridging the Gap: Leveraging AI Technology & Partnerships to Meet DIDO Benchmarks for LVO Patients,” led by Caezar G. Jara at Adventist Health + Rideout, evaluated the impact of the Viz.ai platform on DIDO times at a regional primary stroke center within a hub-and-spoke network. For stroke patients in regional or community settings, DIDO time is a critical determinant of outcomes. Following implementation of a comprehensive quality improvement initiative — including deployment of the Viz.ai platform, partnership with a comprehensive stroke center, and standardized transfer protocols — average DIDO times decreased from 202 minutes to 113 minutes, exceeding the Joint Commission’s 120-minute national benchmark by nearly 6%.
Performance gains were driven by faster LVO identification and team activation, including an 84% reduction in time from CTA completion to detection and reducing care-team notification from 45 minutes to 7 minutes. These workflow changes occurred in the context of implementing Viz.ai’s real-time imaging analysis and automated care coordination capabilities as part of the broader quality improvement effort.
“Our initiative was driven by the need to eliminate manual bottlenecks that delay stroke care in regional settings,” said Caezar G. Jara, BSN, CEN, SCRN, ASC-BC, Stroke Program Manager, Adventist Health + Rideout. “By integrating Viz.ai, we replaced a complex transfer process with an automated, real-time workflow, helping patients reach life-saving intervention sooner.”
In acute ischemic stroke, every minute of delay results in the loss of 1.9 million neurons1. By significantly reducing time to definitive care, the Viz.ai platform enables faster access to endovascular reperfusion therapy, which is associated with improved functional outcomes and reduced disability.
“The data presented at ISC 2026 underscores the power of AI-powered care coordination to expand equitable access to advanced stroke care across regional and community settings,” said Chelsea Summerour, MSN, RN, CNOR, Associate Director of Product at Viz.ai. “Achieving nearly a 90-minute reduction in DIDO time relative to historical performance and aligning with American Heart Association Get With The Guidelines® (AHA–GWTG) transfer standards represents a measurable clinical and system-level advancement, accelerating access to endovascular therapy for patients who might otherwise face preventable delays.”
At ISC 2026, Viz.ai also highlighted continued innovation across its platform, including Viz Assist, designed to further support regional and community hospitals. Viz Assist integrates real-time patient context, automates care-team activation, standardizes transfer workflows, and streamlines inter-hospital communication. By aligning imaging insights with operational coordination across hub-and-spoke networks, Viz Assist helps reduce variability in transfer decision-making and accelerates access to endovascular reperfusion therapy.
About Viz.ai
Viz.ai is the leader in building and deploying AI-powered Care Pathways and helping doctors do their work. The Viz Platform is deployed in 2,000 hospitals across the United States and trusted by many of the leading life sciences companies. The platform uniquely combines real-time, multimodal clinical data with deep clinician engagement to detect disease earlier, coordinate care teams, and help ensure patients receive the right treatment faster. Viz.ai was the first company to be awarded CMS reimbursement for AI and is ranked the #1 Healthcare AI Platform by hospitals and health systems in the Black Book Research survey. For more information, visit Viz.ai.
- Saver JL. Time is brain—quantified. Stroke. 2006;37(1):263-266. doi:10.1161/01.STR.0000196957.55928.ab
Contacts
Media Contact
Caroline Rueve
[email protected]
